ArticleFrontiers in pediatrics2025
Antimicrobial susceptibility and molecular characteristics of
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mycoplasma pneumoniae (MP) is a primary cause of pediatric pneumonia, with rising macrolide resistance being a global concern. Data on its molecular epidemiology and resistance patterns in Xi'an, China, are limited. This study aimed to characterize MP isolates from children in Xi'an to inform local treatment strategies. Methods: In 2023, throat swabs were collected from 376 children hospitalized with MP infection. From these, 70 MP isolates were cultured. Antimicrobial susceptibility testing was performed, and isolates were genotyped using PCR-MALDI-TOF MS to identify P1 types and mutations in the 23S rRNA gene associated with macrolide resistance. Results: The MP culture-positive rate was 18.61% (70/376), with the highest prevalence in school-aged children (5-14 years, 81%). The P1-I genotype was predominant (97%). All 70 isolates harbored A2063G, A2064T, and A2617C mutations in the 23S rRNA gene. However, phenotypic resistance was 38.6% for macrolides, 31.4% for quinolones, and 38.6% for tetracyclines, indicating a significant genotype-phenotype discordance for macrolides. Conclusion: MP strains in Xi'an show high rates of genotypic macrolide resistance and a predominance of the P1-I genotype. The notable discordance between the universal presence of resistance mutations and observed phenotypic resistance underscores the importance of integrating both molecular and culture-based susceptibility testing to guide effective clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.